Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | TOP1 | P11387 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225647 | 1.00 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL1050772 | 1.00 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL30697922 | 1.00 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL4369463 | 0.93 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL4368590 | 0.93 | METTL3 (0.81) | METTL3MAPTKDM4ECFDGAA | |
| Biphenyl SCHEMBL1052588 | 0.92 | METTL3 (0.70) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL16481909 | 0.92 | METTL3 (0.80) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL4371718 | 0.92 | METTL3 (0.80) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL1052589 | 0.91 | METTL3 (0.68) | METTL3MAPTKDM4ECFDGAA | |
| SCHEMBL13861860 | 0.91 | METTL3 (0.72) | METTL3MAPTCFDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20200147086-A1 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | SAINT LOUIS UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190185433-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2018-02-01 | — | — | US | disclosed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | JAPAN TOBACCO INC. | 2015-06-25 | — | — | US | disclosed |
| US-20150141457-A1 | ELVITEGRAVIR SOLID DISPERSION | HETERO RESEARCH FOUNDATION (IN) | 2015-05-21 | — | — | US | disclosed |
| WO-2013175505-A1 | ELVITEGRAVIR SOLID DISPERSION | HETERO RESEARCH FOUNDATION (IN) | 2013-11-28 | — | — | WO | disclosed |
| EP-2197847-B1 | DEUTERATED 4 -OXOQUINOLINE DERIVATIVE FOR THE TREATMENT OF HIV INFECTION | CONCERT PHARMACEUTICALS INC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-7994194-B2 | 4-oxoquinoline derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141457-A1 | ELVITEGRAVIR SOLID DISPERSION | KIF20B, KIF20A, CYP2C18 | METTL3 1858/4885MAPT 1277/4885KDM4E 262/4885 |
| US-20150174117-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, CDKL4, IMPDH2 | METTL3 1398/4885MAPT 3144/4885KDM4E 112/4885 |
| US-20090143427-A1 | 4-Oxoquinoline derivatives | CYP3A4, PIK3CA, CYP3A5 | METTL3 2275/4885MAPT 2253/4885KDM4E 153/4885 |
| US-20190185433-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, RCC1, SFPQ | METTL3 133/4885MAPT 626/4885KDM4E 248/4885 |
| US-20230190730-A1 | 4-OXOQUINOLINE COMPOUND AND USE THEREOF AS PHARMACEUTICAL AGENT | IMPDH1, IMPDH2, DNTT | METTL3 1258/4885MAPT 2829/4885KDM4E 92/4885 |
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | METTL3 278/4885MAPT 3937/4885KDM4E 2049/4885 |
| US-20200147086-A1 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | DNTT, APRT, RNGTT | METTL3 1229/4885MAPT 3444/4885KDM4E 3002/4885 |
| US-20180029989-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | KCNQ2, RCC1, SFPQ | METTL3 133/4885MAPT 626/4885KDM4E 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.